GILT expression in melanoma cells is anticipated to promote anti-tumor immunity by facilitating the presentation of MHC class II-restricted peptides by tumor cells in the microenvironment, which are the same set of epitopes presented by APCs and involved in priming CD4 T cell responses. Here, CD4 is linked to neoplasm.